Reducing non-human primates in non-clinical safety assessment: The European initiative on minipig and micropig models
Project factsheets
Learn more about the projects supported by IHI as well as the Innovative Medicines Initiative (IMI).
Displaying 30 projects and 0 programmes
Developing and implementing virtual control groups to reduce animal use in toxicology research
Accelerating research & development for advanced therapies
Collaboration for prevention and treatment of MDR bacterial infections
Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation
EBiSC2 – A sustainable European bank for induced pluripotent stem cells
European Quality In Preclinical Data
Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management
Integrated immunoprofiling of large adaptive cancer patients cohorts
ITCC pediatric preclinical POC platform
Machine learning ledger orchestration for drug discovery
Neurotoxicity de-risking in preclinical drug discovery
Real world handling of protein drugs - exploration, evaluation and education
Rheuma Tolerance for Cure
Accelerating development and improving access to CAR and TCR-engineered T cell therapy
Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
WEB-RADR 2
Be The Cure
Drug Disease Model Resources
European Autism Interventions - a Multicentre Study for Developing New Medications
Understanding chronic pain and improving its treatment
Improving beta-cell function and identification of diagnostic biomarkers For treatment monitoring in diabetes
Kinetics for Drug Discovery
Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury
Novel methods leading to new medications in depression and schizophrenia
Methods for systematic next generation oncology biomarker development
Oral biopharmaceutics tools
Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development
Physical Activity as a Crucial Patient Reported Outcome in COPD
Surrogate markers for micro- and macro-vascular hard endpoints for innovative diabetes tools